IFNA2 and COVID-19: As controls, we tested a commercial mAb against IFN-α2, a sample from a patient with auto-Abs neutralizing 10 ng/mL IFN-α2, and samples from three patients with life-threatening COVID-19 and three healthy controls without detectable auto-Abs against type I IFNs.